Clinical Trials Logo

CAR-T Cell Therapy clinical trials

View clinical trials related to CAR-T Cell Therapy.

Filter by:
  • None
  • Page 1

NCT ID: NCT06222853 Recruiting - Clinical trials for Systemic Lupus Erythematosus

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Systemic Lupus Erythematosus

Start date: January 4, 2024
Phase: Phase 1
Study type: Interventional

This is an investigator-initiated trial aimed at assessing the safety and efficacy of anti-CD19 CAR-T cells in the treatment of childhood-onset refractory systemic lupus erythematosus.

NCT ID: NCT06196294 Not yet recruiting - Lung Cancer Clinical Trials

GPC3/Mesothelin-CAR-γδT Cells Against Cancers

Start date: January 10, 2024
Phase: Phase 1
Study type: Interventional

The third generation of GPC3/mesothelin targeted CAR-γδT cells have been constructed and their anti-cancer function has been verified by multiple in vitro and in vivo studies. Clinical studies will be performed to test anti-cancer function of the CAR-γδT cells for immunotherapy of human cancer patients with GPC3 or Mesothelin expressions. In this phase I study, the safety, tolerance, and preliminary efficacy of the GPC3/Mesothelin-CAR-γδT cell immunotherapy on human cancers will firstly be evaluated.

NCT ID: NCT05858684 Recruiting - CAR-T Cell Therapy Clinical Trials

Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients

Start date: May 11, 2023
Phase: Early Phase 1
Study type: Interventional

This is an early exploratory phase, single arm, non-randomized, open label, treatment study trial to determine the maximum tolerated dose of GC012F injection (CD19-BCMA CAR-T cells) in patients with refractory systemic lupus erythematosus.

NCT ID: NCT05779917 Recruiting - Pancreas Cancer Clinical Trials

Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers

Start date: March 10, 2023
Phase: Phase 1
Study type: Interventional

The second generation of mesothelin targeted CAR-T cells that secret a fusion protein of IL21 and scfv against PD1 have been constructed and their anti-cancer function has been verified by multiple in vitro and in vivo studies. Clinical studies will be performed to test anti-cancer function of the CAR-T cells for immunotherapy of human cancer patients with Mesothelin expressions. In this phase I study, the safety, tolerance, and preliminary efficacy of the Mesothelin-CAR-T cell immunotherapy on human cancers will firstly be evaluated.

NCT ID: NCT04280133 Active, not recruiting - Clinical trials for Hematologic Malignancy

CAR T-CELL Therapy Educational Video Trial

Start date: May 25, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to test a new educational video to help patients and doctors talk about CAR-T cell therapy, a treatment being used in cancer. - Educational video tool for patients receiving CAR-T cell therapy.